Skip to main content

Advertisement

Table 2 Correlation between FGFR1 gene amplification and the clinicopathological variables

From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis

Parameter Number of samples Positive FGFR1 amplification number (%) P value
Age 478   0.027
   <50 years 152 7 (4.6)  
   ≥50 years 346 35 (10.1)  
Grade 478   Not significant
   1 116 10 (8.6)  
   2 141 12 (8.5)  
   3 221 20 (9.0)  
Size 478   Not significant
   ≥1.5 cm 311 30 (9.6)  
   >1.5 cm 167 12 (7.2)  
Lymph node stage 475   Not significant
   N0 322 28 (8.7)  
   N1 110 9 (8.2)  
   N2 43 4 (9.3)  
Nottingham Prognostic Index 475   Not significant
   Good 175 14 (8.0)  
   Moderate 239 21 (8.8)  
   Poor 61 6 (9.8)  
Distant metastasis 478   0.050
   No 394 30 (7.6)  
   Definite 84 12 (14.3)  
Vascular invasion 467   Not significant
   No 337 27 (8.0)  
   Yes 130 14 (10.8)  
Oestrogen receptor 453   Not significant
   Negative 140 10 (7.1)  
   Positive 313 27 (8.6)  
Progesterone receptor 449   0.084
   Negative 206 22 (10.7)  
   Positive 243 15 (6.2)  
HER2 445   0.043
   Negative 259 28 (10.8)  
   Positive 186 10 (5.4)  
Androgen receptor 415   Not significant
   Negative 188 18 (9.6)  
   Positive 227 13 (5.7)  
Cytokeratin 7/8 467   Not significant
   Negative 167 17 (10.2)  
   Positive 300 24 (8.0)  
Cytokeratin 18 396   Not significant
   Negative 116 7 (6.0)  
   Positive 280 23 (8.2)  
Cytokeratin 19 464   Not significant
   Negative 95 10 (10.5)  
   Positive 369 30 (8.1)  
Cytokeratin 5/6 465   Not significant
   Negative 350 34 (9.7)  
   Positive 115 6 (5.2)  
Cytokeratin 14 458   Not significant
   Negative 357 33 (9.2)  
   Positive 101 6 (5.9)  
Epidermal growth factor receptor 351   Not significant
   Negative 292 26 (8.9)  
   Positive 59 3 (5.1)  
Basal markers [27] 455   Not significant
   Negative 311 31 (10.0)  
   Positive 144 8 (5.6)  
Nielsen groups [28] 396   Not significant
   HER2 39 3 (7.7)  
   Basal-like 55 3 (5.5)  
   Luminal 302 26 (8.6)